Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Inclusion Criteria: * Patients with clinically proved superficial bladder cancer (Ta G1/G2 or T1G1/G2) 2 - 7 weeks before transurethral resection * Written informed consent for study participation and for documentation of disease data including further distribution of these data Exclusion Criteria: * Muscle invasive bladder carcinoma and/or carcinoma in situ (CIS) * Intravesical instillation therapy within 6 months prior to study enrolment * Radiotherapy of the bladder prior to study enrolment * Contracted bladder (capacity less than 100 ml) * Non treated acute or chronic urinary tract infection * Allergy against mistletoe extract preparations * Subvesical obstructions (e. g. prostate hyperplasia, urethral stenosis, residual urine volume more than 80 ml) * Severe illnesses and circumstances not permitting study participation (e. g. alcoholism or substance abuse) * Pregnancy or lactation (pregnancy test if required) as well as women without sufficient contraception * Participation in another clinical study within 30 days prior to this study * Administration of immunotherapeutic and/or cytostatic drugs within 4 weeks prior to study enrolment * Chronic progressive infections (e. g. tuberculosis) * Pre-treatment with mistletoe extracts/mistletoe lectins